Pharmcadd
PharmCADD is a drug discovery platform that combines quantum mechanics, molecular docking, molecular dynamics, and AI to predict protein structures and design new drug candidates. The company's Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics to accelerate the drug discovery process. PharmCADD also develops PharmVAC, an mRNA vaccine platform designed to accelerate treatment…
Funding snapshot
About
PharmCADD is a drug discovery platform that combines quantum mechanics, molecular docking, molecular dynamics, and AI to predict protein structures and design new drug candidates. The company's Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics to accelerate the drug discovery process. PharmCADD also develops PharmVAC, an mRNA vaccine platform designed to accelerate treatment effects on patients. The company is developing drugs targeting NAOC, cancer, Alzheimer's disease, and COVID-19, with active research in quantum computing applications for drug development through partnerships with organizations including MegazoneCloud. The platform has published research on molecular dynamics simulations of MEK1/2 kinase allosteric inhibitors and quantum mechanics-based molecular dynamics methodologies. Founded in 2019 and headquartered in Busan, South Korea, the company has raised $22.0M in Series B funding from investors including Huons, Samyang Holdings, SD Biosensor, Daily Partners, KTB Network, KBD Capital, Maple Investments, DSC Investment, KB Securities, and GNTech Venture Capital.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics,
Oncology > Drugs > Diversified,
Infectious Diseases > Drugs > Viral > COVID-19,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.